Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
activist, aflibercept, Allan, bevacizumab, BReast, capecitabine, CAPEOX, CAPIRI, colon, colorectal, conventional, CRC, database, distant, Dmitry, DNA, doublet, dual, East, EGFR, exposure, fluoropyrimidine, FOLFIRI, FOLFOX, FOLFOXIRI, gap, gastrointestinal, GLOBOCAN, heading, hypercoagulability, ICI, illiquid, inhibition, internationally, irinotecan, leadership, left, lesser, lung, lymph, main, mainstay, mCRC, MD, microsatellite, Middle, mismatch, MMRp, modest, MSS, NALIRIFOX, NCI, neoantigen, newer, odd, older, oncologist, Opdivo, oversee, oxaliplatin, paired, payroll, phishing, proficient, ramucirumab, resection, role, safeguard, School, scientist, stable, steady, surgical, tailored, threat, trastuzumab, triplet, Tsung, uncommon, University, unusual, upcoming, urgent, UVA, vast, VEGFR, versa, Virginia, virtual, vital, vivo, war, XDNASE, Yervoy, younger
Removed:
accelerating, acting, allogeneic, autoleucel, axicabtagene, beneficially, billion, brexucabtagene, Breyanzi, Bristol, ciloleucel, consisting, counterproductive, dated, deducting, delisted, discourage, distancing, EU, executed, FASB, Gilead, granting, growing, intrinsic, Kite, Kymriah, lisocabtagene, macroeconomic, maraleucel, mechanism, parent, penny, pocket, premature, proof, receivable, repayment, secondary, shortage, social, Squibb, TCR, thousand, tisagenlecleucel, ultimate, Yescarta
Financial report summary
?Competition
Eisai • Immunomedics • Immunogen • Alkermes • Incyte • Astrazeneca • Arqule • Durect • Macrogenics • AlkermesManagement Discussion
- The table below sets forth the comparison of our historical results of operations for the year ended December 31, 2023 to the year ended December 31, 2022.